Blog

Jul 23, 2025, 08:08

Proceedings of the 1st Biannual Bridging the Gaps in Lung Cancer Conference – Florez Lab

Florez Lab shared a post on X:

“Just published: Proceedings of the 1st biannual bridging the gaps in lung cancer conference – a landmark conference uniting top oncology experts to tackle today’s biggest controversies in lung cancer care.

Let’s dive into the key takeaways.

Why this matters:

Lung cancer remains the leading cause of cancer death worldwide. Advances in targeted and immunotherapies have helped – but they’ve also made treatment decisions more complex for clinicians.

Experts identified 7 core topics:

1. Biomarkers and testing
2. SCLC
3. EGFR-mutated NSCLC
4. Early-stage NSCLC
5. KRAS/BRAF/MET/other mutations
6. Immunotherapy in advanced NSCLC
7. Practice-changing controversies and consensus needs

Biomarkers and Testing

Challenges include:

• Underutilization of NGS
• Delays in test-to-treatment time
• Need for standardization of reports
• Gaps in access to tissue or ctDNA assays, especially in SCLC

SCLC – Call to action:

• Better trials that reflect real-world patients
• Guidance for maintenance, 2L+ therapies
• Education for community oncologists
• Explore liquid biopsy and SCLC-I subtypes

EGFR-mutated NSCLC – What’s missing:

• Frontline therapy selection guidance
• Treatment post-progression (esp. w/ MET or 797S mutations)
• Resistance mechanisms
• Role of ctDNA and CNS monitoring

Early-Stage NSCLC – Priorities include:

• Increasing screening (especially for never/light smokers)
• Defining perioperative strategies
• Role of MRD, PD-L1, driver mutations
• Coordinated multidisciplinary care

KRAS/BRAF/MET/ALK/RET/NTRK Panel urged:

• Better genetic screening pipelines
• Addressing resistance
• Access to emerging therapies
• Clear 2L standards for rare fusions +Minimizing toxicity and financial burden

Immunotherapy in Advanced NSCLC Still unclear:

• What’s best for PD-L1 ≥50% vs <50%?
• Continue Immunotherapy through progression or rechallenge later?
• Where do ADCs fit in?
• What about leptomeningeal disease?

The common thread across all sessions?

– Multidisciplinary collaboration
– Need for real-world data
– Validation of biomarkers
– Consensus guidelines

Want to read the full proceedings of the 1st Bridging the Gaps in Lung Cancer Conference?

Insight-rich summary of clinical controversies, knowledge gaps, and where we go from here in lung cancer care.”

lung cancer

Title: Proceedings of the 1st biannual bridging the gaps in lung cancer conference

Authors: Narjust Florez , Sandip P Patel , Heather Wakelee , Lyudmila Bazhenova , Erminia Massarelli , Ravi Salgia , Brendon Stiles , Solange Peters , Jyoti Malhotra , Shirish M Gadgeel , Jorge J Nieva , Michelle Afkhami , Fred R Hirsch , Matthew Gubens , Tina Cascone , Benjamin Levy , Joshua Sabari , Hatim Husain , Patrick C Ma , Leah M Backhus , Puneeth Iyengar , Percy Lee , Russell Miller , Jacob Sands , Edward Kim

You can read the Full Article in The Oncologist.

Proceedings of the 1st Biannual Bridging the Gaps in Lung Cancer Conference - Florez Lab

More posts featuring Florez Lab on OncoDaily.

Benjamin Levy Brendon Stiles cancer Edward Kim Erminia Massarelli Fred R. Hirsch Hatim Husain Heather Wakelee Jacob Sands Jorge J Nieva Joshua Sabari Jyoti Malhotra Leah M Backhus Lung cancer Lyudmila Bazhenova Matthew Gubens Michelle Afkhami Narjust Florez OncoDaily Oncology Patrick C. Ma Percy Lee Puneeth Iyengar Ravi Salgia Russell Miller Sandip P Patel Shirish M. Gadgeel Solange Peters Tina Cascone

Hung Trinh: Generation of CAR T Cells Using Lentiviral Vector

Oncologist Near Me – Paolo Tarantino: Shaping the Future of Breast Cancer Treatment

ASCO 2026 Presidential Theme: Dr. Eric Small’s Vision to Translate Science Into Global Cancer Impact

Ravi B. Parikh: Is Accelerated FDA Approval 23 Times Stronger than the Traditional?

Habib Nehmé: The U.S. Market Remains Elekta’s Most Strategic and Significant One